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Introduction
In a series of seminal studies in the early 1900's, Otto Warburg defined unique metabolic features of cancer cells (1) (2) (3) (4) . These metabolic changes are critical fortumor cell survival, proliferation, and metastatic potential (1) (2) (3) (4) (5) . However, it was not until recently that cancer cell metabolism became the focus of intense investigation (1-11).
Nicotinamide adenine dinucleotide (NAD) is a crucial co-factor in redox reactions in metabolic pathways of nearly every cell (7, 12) . It has been shown that NAD participates in multiple physiological processes (7, (13) (14) (15) (16) (17) (18) (19) (20) . In addition, NAD metabolism appears to have a crucial role in fate of tumor cells (21) (22) (23) (24) . Cellular NAD levels are maintained at stable levels via equilibrium between NAD degradation and NAD synthesis. NAD synthesis is mediated by two distinct mechanisms, the salvage and the de novo pathway (7, 12) . NAD degradation is mainly regulated by CD38 (13-18), with other enzymes including sirtuins, Poly (ADP-ribose) polymerases (PARPs), and ADP-ribosyltransferases (ARTs) playing a complementary role.
In this study, we investigated a novel hypothesis that the interplay between (NAD) synthetic and degrading pathways was involved in the regulation of pancreatic tumorigenesis. We studied how inhibition of Nampt, the rate limiting enzyme of the salvage pathway, affects NAD levels, metabolism, cellular energy production, and tumorigenesis. We also studied the role of NAD degrading enzymes in modulating this response.
Research. 
Material and methods

Cell lines
PaTu8988t, Panc-1, SU86.86, Panc04.03 and HPDE cells were provided by Dr. D.
Billadeau or from ATCC. Cultures used for experiments were reinitiated every [4] [5] [6] months from the cryopreserved stocks. The pancreatic cancer cells lines possess K-ras and/or p53 mutations that were validated by DNA sequence analysis using published primers flanking each mutated exon. PaTu8988t and Panc-1 cells were maintained in high-glucose DMEM supplemented with 10% FBS and penicillin/streptomycin (Invitrogen, Eugene, OR, USA). SU86.86 and Panc04.03 cells were grown in RPMI medium supplemented with 10% FBS and penicillin/streptomycin. HPDE cells were grown in SFM-keratinocyte medium supplemented with 5 ng/ml of EGF and 50 µg/ml of bovine pituitary extract. For all the experiments, cells were maintained in media containing 1% FBS for at least 48 hours unless specified.
Reagents and antibodies
Except when specified, all reagents and chemicals were purchased from Sigma Chemical.
Antibodies were from: CD38 (Epitomics), Nampt (Bethyl), NaprT1 (Proteintech), P21 (Santa Cruz Biotechnology). EX527 was from Cayman .PARP-1 inhibitor (4-amino-1,8-naphthalimide) was from Enzo Life Sciences.
MTT assay and trypan blue dye exclusion assay
Cells were plated in 96 well plates (3-5x10 
Short interfering RNA
Non-targeting siRNA (Dharmacon # D001210-03-20) was used as control. For CD38 siRNAs IDT (HSC.RNAI.N001775.12.2) and Dharmacon (J-004581-06) were used. Nampt siRNAs were a pool of 3 target-specific siRNAs (sc-45843, Santa Cruz), and a human on-target plus probe (J-009222-05, Dharmacon). Transfections were performed with 50 nM of siRNA using Lipofectamine RNAiMAX (Invitrogen) according to the manufacturer's instruction.
Transfection and western-blots
Panc-1 cells were transfected with Flag or Flag-CD38 vector using lipofectamine 2000 (Invitrogen). For stable transfections Panc-1 cells were co-transfected with Flag-CD38/puromycin vector or Flag-vector/puromycin vector and selected with 4 µg/ml of puromycin. Western-blots were performed using standard laboratory techniques as described before (14, 16) .
β-Galactosidase staining
Cells were washed in PBS, fixed for 10 min with 3% formaldehyde, washed and incubated for 24 hours at 37 o C with β-Gal staining solution: X-Gal 1 mg/ml, 40 mM citric acid, sodium phosphate (pH 6.0), 5 mM potassium ferrocyanide, 5 mM potassium ferricyanide, 150 mM NaCl, 2 mM MgCl 2 .
Soft agar colony formation assay
Cells were seeded at a density of 10,000/well in 6-well plates in 0.35% agar over 0.6% bottom agar layer in growth media containing 5% FBS and increasing concentrations of FK866. Cell colonies were grown in a humidified 5% CO 2 incubator at 37 °C. Colonies measuring ≥ 50 µm were counted after 7-10 days of culture using a cell colony counter (Gelcount, Oxford Optronix). Experiments were repeated 3 times, each in triplicates.
NAD quantification and NADase activity.
NAD was measured by an enzymatic cycling assay as extensively described by us (14, 16, 18) . NADase activity was determined by us using etheno-NAD as a substrate (14, (16) (17) (18) .
Determination of glycolytic intermediates
Nuclear magnetic resonance (NMR) metabolomic analysis was performed with Glucose 
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ATP measurements
ATP levels were measured in tumor tissues using the Aposensor ATP luminescence assay from BioVision, and in cells using the ATPlite Luminescence assay system from PerkinElmer.
Lactate production
Lactate assay was performed using hydrazine/glycine buffer (pH 9.2), 5mg/mL β-NAD + and 15 units/mL lactate dehydrogenase. NADH formation was monitored at 340nm (25) .
Oxygen Consumption of intact cells
O 2 consumption rates were measured polarographically using high-resolution respirometry (Oroboros-O2K, Insbruck, Austria). FK886 or vehicle treatment cells were used to measure oxygen consumption at the same time at 37 0 C (26). After recording routine (basal) oxygen consumption in DMEM-serum free, oligomycin 2μg/mL was added to inhibit ATP synthesis (leak respiration), followed by titration with the uncoupler FCCP (carbonyl cyanide p-trifluoromethoxyphenylhydrazone) until it reached maximum uncoupled respiration (0,2 -2,5μM). 2μM Rotenone was added to inhibit complex I.
Oxygen consumption after rotenone (not-mitochondria related) was subtracted from all other oxygen consumption measurements. Coupled respiration was calculated as the difference between routine and leak respiration. TaqMan Gene Expression Assay probe sets (Applied Biosystems) were used for analysis of 18s (Hs99999901_s1), Nampt (Hs00237184_m1) and CD38 (Hs01120071_m1). The data was analyzed using the standard curve method. Gene expression was normalized to 18S.
Tumor xenograft study
RNA was isolated from pancreatic cell lines using the RNeasy kit (Qiagen). TaqMan 
Statistical analysis
Data are expressed as means ± SD from at least 3 independent experiments. Data was analyzed using unpaired t-test, one-way and two-way ANOVA. Significance was set at p < 0.05. 
Results
Nampt plays a key role in maintaining NAD levels in pancreatic cancer cells
We evaluated Nampt expression in a panel of pancreatic cancer cell lines and a normal pancreatic cell line (HPDE). We found that Nampt was expressed in all cell lines (Fig.   1A) , with a higher expression in the cell lines Panc04.03 and SU86.86. Next, we examined if inhibition of Nampt using FK866 resulted in a reduction in cellular NAD levels (Fig. 1B) . The effect of FK866 on intracellular NAD levels was variable between the cells tested, with some cells (e.g. PaTu8988t) very sensitive to Nampt inhibition and other cells like Su86.86 showing a significant lower sensitivity to FK866 (Fig. 1B) . To confirm the role of Nampt in the regulation of cellular NAD levels, we tested the effect of an acute reduction in the enzyme expression via knock-down with siRNA in PaTu8988t and Panc-1 cells. Treatment with Nampt siRNA reduced Nampt expression and NAD levels in these cells (Fig. 1C and D) , indicating that the salvage pathway of NAD synthesis plays a key role in maintaining NAD levels in these pancreatic cancer cells.
To determine if FK866 can cause a decrease in overall metabolism in pancreatic cancer cells, we measured several metabolic parameters. First, we observed that glucose consumption was severely impaired in cells treated with FK866 ( Fig. 2A) . NAD is important for several biochemical processes including oxi-reduction reactions of the glycolytic pathway (27) . We observed an accumulation of the glycolytic intermediary investigated the effect of FK866 on mitochondrial oxygen consumption, ATP levels, and the activation of AMP-activated protein kinase (AMPK). FK866 treatment decreased mitochondrial maximum respiratory capacity ( Fig. 2C and Supplementary Fig. S1 ), ATP levels ( Fig. 2D) , and induced phosphorylation/activation of AMPK in pancreatic cancer cells (Fig. 2D) , confirming that Nampt inhibition promotes energy collapse in pancreatic cancer cells.
Inhibition of Nampt decreases pancreatic cancer cell growth and survival
We examined the role of Nampt in the growth and survival of the pancreatic cancer cells.
FK866 cause a dose-dependent inhibition of viability in Panc-1 and PaTu8988t cells (Fig.   3A ). We observed a significant difference in the sensitivity of cells to Nampt inhibition, with PaTu8988t cells being nearly 10 times more sensitive than other cells. The least sensitive was the normal pancreatic cell HPDE ( Fig. 3 and Supplementary Fig. S2 ). Since the MTT assay determines cell viability via an NAD-dependent mechanism we further confirmed our findings with two other complementary assays to measure cell growth and viability (Fig. 3) .
Panc-1 and PaTu8988t cells were treated with 50 nM FK866 for 72 hours and viable cells were counted by the Trypan blue exclusion assay. Treatment with FK866 decreased the number of viable cells in both cells lines (Fig. 3B) .
We determined whether Nampt can regulate anchorage-independent cell growth, an indicator of malignant behavior. Pancreatic cancer cells were treated with FK866 and colony formation in soft agar was measured. Colony formation was decreased by treatment with FK866 in PaTu8988t cells and to a lesser extent in Panc-1 cells (Fig. 3C) .
Furthermore, we knocked-down Nampt using two different siRNAs. Nampt siRNAs inhibited cell growth in both Panc-1 and PaTu8988t cell lines (Fig3D and Supplementary   Fig. S3 ).
NAMPT inhibition impairs pancreatic tumor growth
We further tested the effect of FK866 in a xenograft animal model of pancreatic tumor.
Nude mice were injected with Panc-1 cells and 10 days after implantation the animals were treated with daily intraperitoneal injections of vehicle or 15mg/kg of FK866.
FK866 treatment decreased tumor size when compare with vehicle (Fig. 4A) . Tumors from mice treated with FK866 had lower cellular NAD and ATP levels (Fig. 4B) , and increased phosphorylation of AMPK (Fig. 4C) . During the treatment, no obvious treatment-related toxicity was observed. Body weight and food intake of both groups of animals remained similar (Fig. 4D) . We conclude that FK866 inhibits pancreatic tumor growth in vivo, by inducing tumoral metabolic collapse.
The effect of FK866 in pancreatic cancer cell viability is reversed by NMN and Nicotinic Acid
Because in cells NAD can be synthesized by both the salvage and the de novo pathway, we explored whether the two pathways were involved in the regulation of pancreatic cancer cell growth. In the salvage pathway, Nampt produces nicotinamide mononucleotide (NMN) from nicotinamide. In the de novo pathway, Nicotinic acid phosphoribosyltransferase (Naprt1) produces nicotinic acid mononucleotide (NaMN) from nicotinic acid. The effect of FK866 on cell viability of PaTu8988t was completely reversed by treatment with the NAD precursors NMN and Nicotinic Acid (Fig. 5A ). In addition, the pattern of expression of Naprt1, the enzyme involved in the de novo 
14 pathway, was similar to the expression of Nampt in the different pancreatic cell lines ( Fig   5A) . These data suggest that both pathways are involved in the modulation of pancreatic cancer cell growth. However, inhibition of the salvage pathway is sufficient to promote energy collapse and cell death in pancreatic cancer cells. Since NAD is necessary for both oxi-reduction and non-oxi-reduction reactions, we further explored whether inhibition of some of the non-oxidative NAD-dependent cellular reactions were involved on the decrease in cellular viability induced by Nampt inhibition.
Two enzymes, PARP-1 and SIRT1 catalyze crucial non-oxidative NAD-dependent reactions. Surprisingly, neither PARP1 nor SIRT1 inhibition recapitulated or modified the effects of Nampt inhibition on cell viability (Fig. 5B) . In addition, transient SIRT1 Decreases in cellular NAD can be achieved by inhibition of NAD synthesis or by an increase in its degradation. The enzyme CD38 is the main NADase in many normal mammalian tissues (13-18). Interestingly, it has been proposed that CD38 expression may be lost during the development of prostate cancer (28) . However, the functional role of CD38 in pancreatic cancer cells or any other solid tumor has not been explored. Here we investigated the role of CD38 in pancreatic NAD metabolism and its role in the effect of the Nampt inhibitor FK866 on cell viability and cell growth. Most cultured pancreatic cancer cells tested had low levels of CD38 expression (Fig. 6A) , except for PaTu8988t, that expresses high amounts of CD38. When we knocked-down CD38 in PaTu8988t cells, there was an increase in NAD levels and a decrease in NADase activity (Fig. 6B) .
Although no significant difference on cell viability was observed after cell knockdown of CD38 (data not shown), the cells that were knocked down for CD38 showed lower sensitivity to FK866 than control cells (Fig. 6B, and Supplementary Fig. S4 ).
In contrast, Panc-1 cells have nearly undetectable levels of CD38 (Fig. 6A ). Transient expression of CD38 increased NADase activity, decreased NAD levels, and increased sensitivity to the effect of FK866 on cell viability (Fig. 6C) . Expression of CD38 in Panc-1 cells did not affect mitochondrial respiration by itself, but it sensitized the cells to the inhibitory effect of FK866 in mitochondrial function (Supplementary Fig. S5A ). Also, overexpression of CD38 in SU86.86 promoted a decrease in NAD levels (data not shown) and a significant decrease in cell viability compared to vector-transfected cells (Supplementary Fig. S5B and C) .
To further explore the role of CD38 in NAD metabolism and cell growth we generated a Panc-1-CD38 stable cell line. This cell line has increased NADase activity and lower 
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NAD levels than the control cell line (Fig. 7A) . In addition, the Panc-1-CD38 cells showed cell growth arrest both in vitro and also in an in vivo xenograft mouse model ( Fig. 7A and B) . These cells also exhibit senescent markers, as measured by β-galactosidase staining and increased p21 protein levels (Fig. 7C) . Moreover, in colony formation assays, Panc-1-CD38 cells showed an increase in sensitivity to the FK866 effect in comparison to the control cells (Fig. 7D) , confirming that CD38 has an important effect in regulating the sensitivity to Nampt inhibition.
Heterogeneous expression of NAD metabolizing enzymes in pancreatic tumor tissues.
We further explored the expression of Nampt and CD38 in pancreatic cancer tumor samples from patients. There was a significant variability in the expression of CD38 and Nampt in pancreatic cancer samples, but, in general, the expression of both Nampt and CD38 were higher in samples from pancreatic tumors than in normal tissue ( Supplementary Fig.6A and B) . To compare these results with data from the pancreatic cancer cell lines, we performed real time PCR in samples from pancreatic cancer cell lines and the control pancreatic cell HPDE. All cells express Nampt and Naprt1, but the expression levels differ between cell lines, with some cancer cells expressing similar levels and others lower levels than the control pancreatic cell ( Supplementary Fig.6C and   D) . In contrast, the only pancreatic cancer cell that expresses high amounts of CD38 is PaTu8988t (Supplementary Fig.6E ). For all the cell lines, the patterns of expression of protein and mRNA had a high correlation with all genes tested (Fig. 1A, 5B, 6A ).
Since we found that the expression of CD38 is low in pancreatic cancer cells in culture, the relatively high expression of CD38 in the pancreatic tumor tissues may be mediated by either inflammatory cell infiltration or by stromal cells. However, it is also possible that pancreatic cancer cells in vivo may express CD38 differently than in vitro.
Discussion
Pancreatic cancer is one of the top five causes of cancer-related deaths around the globe, with an extremely poor prognosis (about 5% survival in 5 years) and a median survival for metastatic disease of about 6 months (29) . New and effective therapies are urgently needed for this disease. The studies described here clearly show a role for the salvage pathway as potential therapeutic target in pancreatic cancer and also identified NAD catabolic pathways that modulate the sensitivity to Nampt inhibitors in cancer models.
Recently, it has been proposed that NAD metabolism may be a potential target for the treatment of cancers (6, 12, (21) (22) (23) (24) 30) . NAD is a crucial co-factor in redox reactions in metabolic pathways of nearly every cell (6, 12) . NAD can be found in two states, 
information published about NAD synthetic pathways in pancreatic cancer cells is a study that showed that colo357 pancreatic cancer cells express Nampt in response to IL-1 treatment (9) . In this regard, characterization of the metabolic pathways for synthesis was one of the goals of our study. We describe for the first time that pancreatic cancer cells use the salvage pathway and rely on the enzyme Nampt for NAD synthesis, and that inhibition of the Nampt enzyme causes pancreatic cancer cell death. The mechanism by which NAD collapse mediated by Nampt inhibition causes cancer cell death has been proposed to be mediated by inhibition of the glycolytic pathway and /or inhibition of the NAD-dependent deacetylase SIRT1 (7, 8, 22, 27, 32) . In our experiments, inhibition of SIRT1 was neither necessary nor sufficient to explain the cellular effects of Namptinhibition in pancreatic cancer cells.
Tumor cells have a highly active "aerobic glycolysis" known as the "Warburg effect" (1-2). Mechanistically, the first reaction in the glycolytic pathway that is dependent on NAD(H) is the conversion of glyceraldehyde 3 phosphate to 1.3 biphosphoglycerate catalyzed by GAPDH (27) . However, the reaction preceding this step, the interconversion of glyceraldehyde 3 phosphate and Fructose-1,6 BP is reversible, and we expected that inhibition of the GAPDH reaction could lead to accumulation of one of these metabolites. 
Another goal of our study was to characterize the NAD catabolizing pathways in pancreatic cancer cells. To our knowledge the mechanisms of NAD degradation in tumor cells have not been well described. In particular, given the emerging interest in developing NAD targeted therapies for human cancers, it is important to determine the mechanisms that modulate NAD-degradation in the setting of inhibition of NAD synthetic pathways.
We observed in cultured pancreatic cancer cells that expression of the NADase CD38 played a key role on the sensitivity of cells to the Nampt inhibitor FK866. In addition, we observed that CD38 and Nampt expression are quite variable between tumors from pancreatic cancer patients (Supplemental Figure 6) , and we propose that the relative expression of Nampt and CD38 may play a key role on the response to salvage pathwaytargeted therapy and may serve as potential biomarkers for the cellular response to Nampt inhibition.
In conclusion, our data provides the first evidence of the role of NAD anabolism and 
